Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable (Stage III) Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00082875
What this trial is testing

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Who this might be right for
Stage III MelanomaStage IV Melanoma
National Cancer Institute (NCI) 56
Testing effectiveness (Phase 2)Ended earlyNCT01551693
What this trial is testing

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Dana-Farber Cancer Institute 3
Early research (Phase 1)Study completedNCT02032810
What this trial is testing

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Not applicableActive Not RecruitingNCT04056247
What this trial is testing

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Who this might be right for
Stage IV Non-small Cell Lung CancerStage IV Malignant MelanomaStage IV Small Cell Lung Cancer+2 more
OncoHost Ltd. 10,000
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01024231
What this trial is testing

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Who this might be right for
Malignant Melanoma
Bristol-Myers Squibb 127
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122522
What this trial is testing

Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Who this might be right for
Metastatic Melanoma
Memorial Sloan Kettering Cancer Center 70
Early research (Phase 1)Study completedNCT01638533
What this trial is testing

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Who this might be right for
GliomaHematopoietic and Lymphoid Cell NeoplasmLymphoma+47 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03999749
What this trial is testing

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 71
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT02073123
What this trial is testing

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Who this might be right for
Metastatic MelanomaStage III MelanomaStage IV Melanoma
NewLink Genetics Corporation 131
Testing effectiveness (Phase 2)Study completedNCT00715793
What this trial is testing

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hussein Tawbi 39
Testing effectiveness (Phase 2)Study completedNCT00327600
What this trial is testing

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Who this might be right for
Malignant Melanoma
AmpliMed Corporation 68
Testing effectiveness (Phase 2)Study completedNCT01009775
What this trial is testing

YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Who this might be right for
Melanoma
Astellas Pharma Inc 64
Large-scale testing (Phase 3)Looking for participantsNCT06246916
What this trial is testing

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Who this might be right for
Melanoma
Regeneron Pharmaceuticals 560
Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Testing effectiveness (Phase 2)WithdrawnNCT04703426
What this trial is testing

Sargramostim (GM-CSF) + PD-1

Who this might be right for
Unresectable MelanomaMetastatic MelanomaStage III Melanoma+1 more
Dana-Farber Cancer Institute
Not applicableStudy completedNCT01715077
What this trial is testing

Study of Ipilimumab in the Immune System

Who this might be right for
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
University Health Network, Toronto 4
Testing effectiveness (Phase 2)Looking for participantsNCT05428007
What this trial is testing

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
MelanomaUnresectable Melanoma
NYU Langone Health 105
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Next Page